IL276871B2 - Dosage forms and methods for enantiomerically enriched or pure bupropion - Google Patents
Dosage forms and methods for enantiomerically enriched or pure bupropionInfo
- Publication number
- IL276871B2 IL276871B2 IL276871A IL27687120A IL276871B2 IL 276871 B2 IL276871 B2 IL 276871B2 IL 276871 A IL276871 A IL 276871A IL 27687120 A IL27687120 A IL 27687120A IL 276871 B2 IL276871 B2 IL 276871B2
- Authority
- IL
- Israel
- Prior art keywords
- bupropion
- dosage form
- dextromethorphan
- fold
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL276871A IL276871A (en) | 2020-10-29 |
| IL276871B1 IL276871B1 (en) | 2024-07-01 |
| IL276871B2 true IL276871B2 (en) | 2024-11-01 |
Family
ID=67688503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276871A IL276871B2 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| IL313368A IL313368A (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313368A IL313368A (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (enExample) |
| JP (3) | JP2021513998A (enExample) |
| KR (3) | KR20210003091A (enExample) |
| CN (2) | CN120827545A (enExample) |
| AU (3) | AU2019223187B2 (enExample) |
| BR (1) | BR112020017179A2 (enExample) |
| CA (1) | CA3092076A1 (enExample) |
| CL (1) | CL2020002166A1 (enExample) |
| CR (1) | CR20200415A (enExample) |
| EC (1) | ECSP20060179A (enExample) |
| IL (2) | IL276871B2 (enExample) |
| MA (1) | MA51914A (enExample) |
| MX (2) | MX2020008704A (enExample) |
| MY (1) | MY202993A (enExample) |
| NI (1) | NI202000056A (enExample) |
| NZ (1) | NZ767378A (enExample) |
| PE (1) | PE20211752A1 (enExample) |
| SG (1) | SG11202008056SA (enExample) |
| WO (1) | WO2019165379A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008704A (es) * | 2018-02-23 | 2020-12-07 | Axsome Therapeutics Inc | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| CA3287347A1 (en) * | 2019-09-20 | 2025-11-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052341A1 (en) * | 1999-03-01 | 2002-05-02 | Sepracor Inc. | Bupropion metabolites and methods of their synthesis and use |
| US20160030420A1 (en) * | 2013-11-05 | 2016-02-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US20170304230A1 (en) * | 2013-11-05 | 2017-10-26 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2483499A (en) * | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| SI1575565T1 (sl) * | 2003-08-08 | 2010-04-30 | Biovail Lab Int Srl | Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| MX2020008704A (es) * | 2018-02-23 | 2020-12-07 | Axsome Therapeutics Inc | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. |
-
2019
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko active Pending
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052341A1 (en) * | 1999-03-01 | 2002-05-02 | Sepracor Inc. | Bupropion metabolites and methods of their synthesis and use |
| US20160030420A1 (en) * | 2013-11-05 | 2016-02-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US20170304230A1 (en) * | 2013-11-05 | 2017-10-26 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021513998A (ja) | 2021-06-03 |
| MX2020008704A (es) | 2020-12-07 |
| JP2024075655A (ja) | 2024-06-04 |
| ECSP20060179A (es) | 2020-12-31 |
| EP3755312A4 (en) | 2022-03-16 |
| AU2019223187B2 (en) | 2022-07-28 |
| PE20211752A1 (es) | 2021-09-06 |
| JP2022153638A (ja) | 2022-10-12 |
| AU2022204521B2 (en) | 2024-09-05 |
| IL313368A (en) | 2024-08-01 |
| KR20230075531A (ko) | 2023-05-31 |
| WO2019165379A1 (en) | 2019-08-29 |
| NZ767378A (en) | 2024-03-22 |
| MY202993A (en) | 2024-05-31 |
| CL2020002166A1 (es) | 2020-10-23 |
| IL276871B1 (en) | 2024-07-01 |
| IL276871A (en) | 2020-10-29 |
| CR20200415A (es) | 2021-02-03 |
| AU2022204521A1 (en) | 2022-07-21 |
| MA51914A (fr) | 2020-12-30 |
| KR20210003091A (ko) | 2021-01-11 |
| CN120827545A (zh) | 2025-10-24 |
| AU2019223187A1 (en) | 2020-09-17 |
| NI202000056A (es) | 2021-01-11 |
| CN112087999A (zh) | 2020-12-15 |
| EP3755312A1 (en) | 2020-12-30 |
| SG11202008056SA (en) | 2020-09-29 |
| BR112020017179A2 (pt) | 2020-12-22 |
| KR20240091043A (ko) | 2024-06-21 |
| MX2023009281A (es) | 2023-08-17 |
| CA3092076A1 (en) | 2019-08-29 |
| AU2024205858A1 (en) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210196704A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11660273B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20210177834A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11660274B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20190216800A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20190216801A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US10695304B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| AU2022204521B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11179352B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11433035B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11331285B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US12102606B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20200222339A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20220249405A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20240277635A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| AU2024200081A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion |